Somerset Pharmaceuticals Overview

  • Founded
  • 1986
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • 2ndary - Private
  • Financing Rounds
  • 2

Somerset Pharmaceuticals General Information

Description

Developer of pharmaceutical products. The company is engaged in the clinical development of a selegiline transdermal system for the treatment of several indications, including Alzheimer's disease, depression and parkinson's disease. It also offers pharmaceutical research and development services.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • 22202 North West Shore Boulevard
  • Suite 450
  • Tampa, FL 33607
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Somerset Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Somerset Pharmaceuticals‘s full profile, request access.

Request a free trial

Somerset Pharmaceuticals Patents

Somerset Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-2478026-A1 Methods for preventing and treating peripheral neuropathy by administering desmethylselegiline Abandoned 04-Mar-2002 0000000000
AU-2003220016-A1 Methods for preventing and treating peripheral neuropathy by administering desmethylselegiline Granted 04-Mar-2002 0000000000
JP-2005525377-A Method for prevention and treatment of peripheral neuropathy by administration of desmethyl selegiline Granted 04-Mar-2002 0000000000
EP-1487427-A1 Methods for preventing and treating peripheral neuropathy by administering desmethylselegiline Withdrawn 04-Mar-2002 0000000000 0
EP-1487427-A4 Methods for preventing and treating peripheral neuropathy by administering desmethylselegiline Withdrawn 04-Mar-2002 A61K31/135 0

Somerset Pharmaceuticals Executive Team (1)

Name Title Board Seat Contact Info
Mel Sharoky President & Chief Executive Officer
To view Somerset Pharmaceuticals’s complete executive team members history, request access »

Somerset Pharmaceuticals Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Somerset Pharmaceuticals‘s full profile, request access.

Request a free trial